Addex Therapeutics (NASDAQ:ADXN) Stock Price Down 0.5% – Here’s Why

Shares of Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) fell 0.5% during trading on Monday . The company traded as low as $5.60 and last traded at $5.6690. 1,217 shares traded hands during trading, a decline of 58% from the average session volume of 2,876 shares. The stock had previously closed at $5.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Addex Therapeutics Price Performance

The firm has a 50 day simple moving average of $6.39 and a 200-day simple moving average of $6.88. The company has a market cap of $6.97 million, a price-to-earnings ratio of -0.95 and a beta of 1.50.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.